Wnt or β-Catenin signaling pathway plays an important role in the development of pluripotent cells. The signaling pathway was earlier named as Wingless (Wng) in Drosophila and Int1 in the mouse. Historically, the Wnt signaling pathway is divided into two subsets, canonical Wnt signaling pathway, and non-canonical Wnt signaling pathway. The canonical Wnt signaling pathway causes the translocation and stabilization of β-catenin into the nucleus. The canonical Wnt signaling pathway via Dishevelled (Dvl) inhibits the formation of “destruction complex”. The non-canonical Wnt signaling pathway includes planar cell polarity pathway that guides cell movement during Wnt/Ca+ signaling pathway and gastrulation.
WNT SIGNALING PATHWAY INHIBITORS THERAPEUTICS CANDIDATES UNDER DEVELOPMENT (2017)
Pharmaceutical companies are using different technologies for better development of drug candidates. These technologies can be helpful in the development of drugs as combination therapies or single agent therapies. They also allow the development of specific targeted therapies with better drug delivery. For instance, Samumed's technology platform can modulate the Wnt signaling pathway in selected tissues with small molecules. The company has discovered numerous new biological processes related to the Wnt signaling pathway, identified novel biological targets, and developed small-molecule drugs that modulate Wnt activity.
As of November 2017, the Wnt signaling pathway inhibitors therapeutics pipeline comprises of approximately 26 drug candidates in different stages of development.
Some of the key players developing drugs as Wnt signaling pathway inhibitors therapeutics include Samumed, LLC, Can-Fite BioPharma Ltd., Tactical Therapeutics, Inc. and others.